Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 50 of 6351
-
Can a new pill help a failing heart pump better?
Disease control Recruiting nowCRD-4730 is a calcium/calmodulin-dependent protein kinase II (CaMKII) inhibitor. The CALIBRATE-HF trial is a Phase 2, global, multi-center, randomized, double-blind, parallel-group, placebo-controlled trial. The trial will evaluate the efficacy, safety, and tolerability of CRD-47…
Phase 2 • Sponsor: Cardurion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a chemo-free cocktail tame mantle cell lymphoma?
Disease control Recruiting nowThis study aims to evaluate the safety and efficacy of orelabrutinib (O) in combination with obinutuzumab (G) and short-course venetoclax (V) in patients with treatment-naïve MCL.
Phase 2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
HIV cocktail aims to free patients from daily pills
Disease control Recruiting nowA modern and urgent challenge in fighting HIV infection is to achieve sustained HIV remission without the use of antiretrovirals. The investigators' preliminary data indicate that the use of combined strategies to mitigate the HIV proviral reservoir size among individuals with su…
Phase 2 • Sponsor: Federal University of São Paulo • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New combo therapy aims to shrink rectal tumors and save organs
Disease control Not yet recruitingThis is a prospective, multicenter, randomized controlled trial aimed at comparing different radiotherapy fractionation regimens combined with sequential dual immunotherapy versus traditional chemoradiotherapy in neoadjuvant treatment for locally advanced rectal cancer (LARC). A …
Phase 2/3 • Sponsor: Beijing Friendship Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Twice-Yearly HIV shots could replace daily pills
Disease control Recruiting nowThe goal of this clinical study is to compare how effective a long-acting injectable treatment of lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) versus (CAB) and rilpivirine (RPV) injections given every 8 weeks in adults with HIV-1 whose virus is well controlled on d…
Phase 3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a One-Two punch fix a leaky heart valve and restore normal rhythm?
Disease control Recruiting nowThis study aims to evaluate the safety and efficacy of combined electrical cardioversion and TEER in patients with severe mitral regurgitation and atrial fibrillation after undergoing TEER. The main objective is to assess the superiority of the combined treatment strategy in redu…
Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a Triple-Drug combo tame a rare heart disease?
Disease control Not yet recruitingThe goal of this clinical trial is to evaluate whether selinexor combined with daratumumab and dexamethasone (XDd) can treat patients with advanced light-chain cardiac amyloidosis. The main questions it aims to answer are: Does XDd regimen achieve hematologic complete response i…
Phase 2 • Sponsor: Beijing Anzhen Hospital • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a patch seal the leak after aortic repair? a new device aims to find out
Disease control Recruiting nowA Multicenter, Randomized Controlled Study About the Safety and Efficacy of WeFlow-EndoPatch Aortic Endovascular Patch System manufactured by EndoNom Medtech (Hangzhou) Co., Ltd. for Chronic Aortic Dissection . (GALLANT Study)
Sponsor: Hangzhou Endonom Medtech Co., Ltd. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Drug could double survival in rare stem cell transplant complication
Disease control Recruiting nowHigh-risk, complement-mediated, untreated transplant-associated thrombotic microangiopathy (hrTA-TMA) carries a very poor prognosis due to multiple organ dysfunction syndrome (MODS). The complement C5 inhibitor eculizumab has shown promising efficacy in children with hrTA-TMA, bu…
Phase 2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New Antibody-Like drug could boost chemo for rare cancer
Disease control Recruiting nowThis study is open to adults with advanced extrapulmonary neuroendocrine cancer. The purpose of this study is to find out if a study medicine called obrixtamig plus standard chemotherapy (carboplatin and etoposide) improves survival when compared to standard chemotherapy (carbopl…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a Three-Day pill ease postpartum depression?
Disease control Recruiting nowThis is a multicenter, randomized, double-blind, placebo-controlled trial consisting of an experimental drug group and a placebo group, each enrolling 100 participants. The objective of this study is to assess the efficacy and safety of MI078 capsules for the treatment of postpar…
Phase 3 • Sponsor: Nanjing Minova Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Could a simple drug infusion stop a dangerous virus after stem cell transplants?
Disease control Not yet recruitingThis is a single-center, prospective, randomized, open-label clinical trial with blinded endpoint assessment for patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). We aim to explore whether low-dose preventive rituximab can lower the risk of clinic…
Sponsor: Yang Donglin • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Could Self-Sampling revolutionize cervical cancer screening?
Diagnosis Recruiting nowTo evaluate whether individuals drawn from the intended use population can successfully interpret and follow the IFU for the Mia by XytoTest self-collection device and perform a vaginal sample collection yielding sufficient cellular material for primary hrHPV screening. To asses…
Sponsor: Mel Mont Medical • Aim: Diagnosis
Last updated Aug 13, 2026 00:00 UTC
-
New stem cell transplant aims to ease severe blood disorders
Disease control Recruiting nowThis is a non-ablative (partial) stem cell transplant for patients with severe sickle cell disease or beta-thalassemia requiring red cell transfusions. The intensity of the transplant is slightly increased from our previous transplant regimens. The goal is to aim for higher perce…
Phase 1/2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New RSV vaccine candidate aims to shield older adults from severe lung infections
Vaccine OngoingThis Phase I/II study is to characterize the safety and immunogenicity of 2 dose levels of AZD6489, an investigational RSV recombinant prefusion F protein VLP vaccine.
Phase 1/2 • Sponsor: AstraZeneca • Aim: Vaccine
Last updated Sep 03, 2026 00:00 UTC
-
Biomarker-Guided therapy aims to outperform standard treatment in advanced esophageal cancer
Disease control Not yet recruitingThis is a prospective, multicenter, randomized, open-label, umbrella superiority clinical trial for patients with advanced metastatic esophageal squamous cell carcinoma who have not received prior anti-tumor treatment. All eligible participants will be randomly assigned into two…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New hope for bile duct cancer: targeted drug BL-M07D1 enters final testing
Disease control Recruiting nowThis trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with HER2-expressing locally advanced or metastatic biliary tract cancer after platinum-containing chemotherapy failure.
Phase 3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New targeted drug aims to outsmart Hormone-Resistant breast cancer
Disease control Recruiting nowThis trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced, recurrent, or metastatic HR+/HER2- breast cancer after failure of prior endocrine therapy.
Phase 3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Smart cancer therapy: tailoring lung cancer treatment with a simple blood test
Disease control Not yet recruitingThis is a multicenter, phase II exploratory clinical trial in untreated patients with EGFR-mutant non-small cell lung cancer (stages IIIB-IV) .All participants will receive oral befotertinib monotherapy for 3 weeks first, then serial minimal residual disease (MRD/MRD) testing is …
Phase 2 • Sponsor: Guangzhou University of Traditional Chinese Medicine • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New triple therapy aims to boost survival in frail AML patients
Disease control Recruiting nowThe goal of this clinical trial is to learn if Venetoclax+Azacytidine+Quizartinib works better than standard therapy (Venetoclax+Azacytdine) to treat naïve adult patients with acute myeloid leukemia (AML) who are not suitable for standard induction therapy due to age, co-morbidit…
Phase 3 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC